Mazyar Shadman, MD, MPH

Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center, presents updated SEQUOIA Arm D results demonstrating deep, durable responses and favorable safety with fixed-duration zanubrutinib plus venetoclax in treatment-naive CLL/SLL, including patients with del(17p)/TP53 mutations.

Dr. Mazyar Shadman presents a network meta-analysis evaluating Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL, showing that zanubrutinib demonstrated the greatest efficacy in reducing progression and death compared to other BTK inhibitors and treatments.

Mazyar Shadman, MD, MPH, discusses the rationale and methodological framework of a network meta analysis of BTK inhibitors in relapsed/refractory CLL.

Mazyar Shadman, MD, MPH, discusses the rationale and methodological framework of a network meta-analysis aimed at evaluating the comparative efficacy of BTK inhibitors in R/R CLL.

Mazyar Shadman, MD, MPH, discusses the need for a clinical consensus in selecting optimal treatment strategies in diffuse large B-cell lymphoma.

Dr Shadman discusses key findings and implications from trials that were presented at the 2024 ASH Annual Meeting investigating zanubrutinib in CLL.

Dr. Mazyar Shadman presents an OncLive Rapid Readout on the SEQUOIA study, highlighting 5-year follow-up data that confirm zanubrutinib’s sustained progression-free survival superiority over bendamustine plus rituximab in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma, with consistent efficacy across risk groups and a favorable long-term safety profile.

Mazyar Shadman, MD, MPH, discusses real-world outcomes following early dose adjustments of first-line ibrutinib in CLL/SLL.

Mazyar Shadman, MD, MPH, discusses the investigation of sonrotoclax in the CELESTIAL-TNCLL trial in treatment-naïve chronic lymphocytic leukemia.

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss ongoing trials and future treatment directions for chronic lymphocytic leukemia.

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss real-world safety data for BTK inhibitors in chronic lymphocytic leukemia from EHA 2024.

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss matching-adjusted indirect comparisons of BTK inhibitors in chronic lymphocytic leukemia.

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss findings from the SEQUOIA trial of zanubrutinib in treatment-naive chronic lymphocytic leukemia.

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss how to use data for BTK inhibitors to inform clinical decisions in chronic lymphocytic leukemia.

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, on factors for selecting a BTK inhibitor or a venetoclax-based regimen in chronic lymphocytic leukemia.

Mazyar Shadman, MD, MPH, discusses the rationale for combining sonrotoclax plus zanubrutinib for treatment-naive chronic lymphocytic leukemia.

This is an evaluation of the results of a network meta-analysis covering the comparative efficacy of bruton tyrosine kinase Inhibitors in relapse/refractory chronic lymphocytic leukemia.

Mazyar Shadman, MD, MPH, discusses results from a network meta-analysis on the comparative efficacy of BTK inhibitors in relapsed/refractory CLL.

Mazyar Shadman, MD, MPH, presents data from a matching adjusted indirect comparison (MAIC) of the efficacy of zanubrutinib versus acalabrutinib in relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) based on data from the Phase 3 ALPINE and Phase 3 ASCEND trials.

Mazyar Shadman, MD, MPH, discusses preliminary long-term findings from the evaluation of zanubrutinib in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were intolerant to ibrutinib and/or acalabrutinib.

Mazyar Shadman, MD, MPH, discusses the efficacy and safety of zanubrutinib in chronic lymphocytic leukemia, as well as data derived from the agents use which supports the regulatory approval of zanubrutinib in this patient population.

Mazyar Shadman, MD, MPH, discusses the exploration of MB-106, a third-generation CD20-targeted autologous CAR T-cell therapy, in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Mazyar Shadman, MD, MPH, discusses the efficacy of MB-106, a CD20-targeted CAR T-cell therapy in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Mazyar Shadman, MD, MPH, discusses the methods utilized in an ongoing phase 1/2 trial evaluating MB-106, an investigational CD20-directed CAR T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Mazyar Shadman, MD, MPH, discusses the safety profile of MB-106, a third-generation, CD20-directed CAR T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Mazyar Shadman, MD, discusses the emergence of third-generation BTK inhibitors in chronic lymphocytic leukemia.

Mazyar Shadman, MD, discusses considerations for BTK inhibitors in the treatment of patients with chronic lymphocytic leukemia.

Mazyar Shadman, MD, discusses continuous vs time-limited treatments for patients with chronic lymphocytic leukemia.

Mazyar Shadman, MD, discusses the role of minimal residual disease in chronic lymphocytic leukemia.

Mazyar Shadman, MD, discusses the potential for CAR T-cell therapy in patients with high-risk chronic lymphocytic leukemia.